Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Wei Chen
Institutions:
Xuzhou Medical College,
Affiliated Hospital of Xuzhou Medical College
Observed institutions:
Xuzhou Medical College,
Affiliated Hospital of Xuzhou Medical College,
Nanjing Medical University
ORCID:
0000-0001-5480-6577
Observed ORCID:
0000-0001-5480-6577
OpenAlex ID:
A5073452528
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
2024
·
Ming Shi
, Jiaojiao Wang
, et al.
·
Nature Communications
·
135
PDF
Anti–G Protein–Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial
2023
·
Jieyun Xia
, Hujun Li
, et al.
·
Journal of Clinical Oncology
·
104
PDF
CD86 Is Associated with Immune Infiltration and Immunotherapy Signatures in AML and Promotes Its Progression
2023
·
Qianqian Zhang
, Ruixue Ma
, et al.
·
Journal of Oncology
·
36
PDF
Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti‐ BCMA CAR T‐cell‐based therapy
2024
·
Yuekun Qi
, Hujun Li
, et al.
·
American Journal of Hematology
·
29
PDF
Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma
2025
·
Sha Ma
, Jieyun Xia
, et al.
·
Blood
·
28
Advances in the Diagnosis and Treatment of Myeloproliferative Neoplasms (MPNs)
2025
·
Xinyu Ma
, Zhibo Zhou
, et al.
·
Cancers
·
14
PDF
Endothelial activation and stress index (EASIX) as a predictive biomarker for survival in patients with T-cell lymphoma
2025
·
Miao Li
, Huimin Chen
, et al.
·
Hematology
·
9
PDF
Mechanisms underlying resistance to CAR-T cell therapy and strategies for enhancement
2025
·
Anran Wu
, Tingying Zhang
, et al.
·
Cytokine & Growth Factor Reviews
·
9
Comprehensive characterization of cytopenia after chimeric antigen receptor-T cell infusion in patients with relapsed or refractory multiple myeloma
2024
·
Hai Cheng
, Lingyan Shao
, et al.
·
Cytotherapy
·
6
PDF
Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease
2026
·
Dian Zhou
, Yuekun Qi
, et al.
·
Blood
·
5
Distinguishing clinical and imaging characteristics of primary central nervous system lymphoma from high-grade glioma and metastatic brain tumors
2024
·
Qian Hu
, Shenyang Zhang
, et al.
·
Clinical & Translational Oncology
·
4
Research progress of targeted BCMA CAR-T therapy for relapsed/refractory multiple myeloma antigen-negative relapse
2025
·
Lulu Kong
, Kailin Xu
, et al.
·
Best Practice & Research Clinical Haematology
·
3
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
2024
·
Ruixue Ma
, Qi Zhang
, et al.
·
Clinical and Experimental Medicine
·
1
PDF
The prognostic significance of POD24 in peripheral T-cell lymphoma
2024
·
Huimin Chen
, Ruixue Ma
, et al.
·
Hematology
·
1
Allo-HSCT Might Improve Long-Term Survival in Patients with CD56-Positive AML
2026
·
Xiaotong Zhu
, Yuting Sun
, et al.
·
Journal of Blood Medicine
PDF
A proliferation-inducing ligand enhances the anti-tumor effect of BCMA CAR T-cell through inhibition of soluble BCMA
2026
·
Huanhuan She
, Jiahan Lin
, et al.
·
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Late phase transfusion after CAR T therapy is associated with persistent hematotoxicity and non-relapse mortality in multiple myeloma: a post hoc analysis
2026
·
Fan Xia
, Bin Lv
, et al.
·
BMC Medicine
Show more works
View as search
Works count:
17
Citation count:
384
H-index:
8
I10-index:
6
Year
Topic
Type